日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Tiragolumab Plus Atezolizumab and Chemotherapy for Advanced Nonsquamous Non-Small Cell Lung Cancer: The Phase 3 SKYSCRAPER-06 Randomized Clinical Trial

Tiragolumab联合Atezolizumab和化疗治疗晚期非鳞状非小细胞肺癌:SKYSCRAPER-06 3期随机临床试验

Socinski, Mark A; Stahel, Rolf; Lee, Dae Ho; Cappuzzo, Federico; Nishio, Makoto; Lovly, Christine M; Ozyilkan, Ozgur; Li, Qingshan; Johnson, Melissa; Garon, Edward B; Kilickap, Saadettin; Ferreira da Silva, Flavio Augusto; Alatorre-Alexander, Jorge; Meng, Raymond; Amin, Reena; Matheny, Christina; Troutman, Sarah; Wen, Xiaohui; Patil, Namrata S; Zou, Wei; Rodriguez-Abreu, Delvys

Macropinocytosis and Vascularization Determine Response to mTOR Inhibitors in Lung Squamous Cell Carcinoma

巨胞饮作用和血管生成决定肺鳞状细胞癌对 mTOR 抑制剂的反应

Brady, Morgan R; Matulionis, Nedas; Christofk, Heather R; Garon, Edward B; Lisberg, Aaron; Shackelford, David B; Momcilovic, Milica

Author Correction: Sensitive detection of tumor mutations from blood and its application to immunotherapy prognosis

作者更正:从血液中灵敏地检测肿瘤突变及其在免疫治疗预后中的应用

Li, Shuo; Noor, Zorawar S; Zeng, Weihua; Stackpole, Mary L; Ni, Xiaohui; Zhou, Yonggang; Yuan, Zuyang; Wong, Wing Hung; Agopian, Vatche G; Dubinett, Steven M; Alber, Frank; Li, Wenyuan; Garon, Edward B; Zhou, Xianghong Jasmine

Correction: cfTrack: A Method of Exome-Wide Mutation Analysis of Cell-free DNA to Simultaneously Monitor the Full Spectrum of Cancer Treatment Outcomes Including MRD, Recurrence, and Evolution

更正:cfTrack:一种对游离DNA进行全外显子组突变分析的方法,可同时监测癌症治疗结果的全谱,包括微小残留病灶(MRD)、复发和演变。

Li, Shuo; Zeng, Weihua; Ni, Xiaohui; Zhou, Yonggang; Stackpole, Mary L; Noor, Zorawar S; Yuan, Zuyang; Neal, Adam; Memarzadeh, Sanaz; Garon, Edward B; Dubinett, Steven M; Li, Wenyuan; Zhou, Xianghong Jasmine

Toward the simultaneous detection of multiple diseases with a highly cost-effective cell-free DNA methylome test

利用高性价比的无细胞DNA甲基化组检测方法同时检测多种疾病

Zeng, Weihua; Liu, Chun-Chi; Li, Shuo; Zhou, Yonggang; Stackpole, Mary L; Xiao, Ying; Hu, Ran; Tang, Caitlin; Liu, Qiao; Zeng, Wanwen; Yeh, Angela; Melehy, Andrew; Tran, Benjamin; Noor, Zorawar; Yokomizo, Megumi; Amara, Dominic; Gumate, Shreya; Ahuja, Preeti; Li, David Yuanze; Zhao, Junting; Rose, Inga; Walker, Cattlena; Malik, Sadaf; Zhu, Yazhen; Tseng, Hsian-Rong; Garon, Edward B; French, Samuel W; Magyar, Clara E; Dry, Sarah M; Lajonchere, Clara M; Geschwind, Daniel; Choi, Gina; Saab, Sammy; Shetty, Akshay; Wong, Carrie R; King, Kevin G; Lu, David S; Raman, Steven S; Xiang, Xiyan; Shetty, Kirti; Mishra, Lopa; Memarzadeh, Sanaz; Liu, Yan; Albe, Frank; Hsu, William; Krysan, Kostyantyn; Dubinett, Steven M; Aberle, Denise R; Agopian, Vatche; Han, Steven-Huy B; Wong, Wing Hung; Ni, Xiaohui; Li, Wenyuan; Zhou, Xianghong Jasmine

Adequacy of Immune Checkpoint Inhibitor-Associated Thyroid Function Monitoring After Therapy

免疫检查点抑制剂治疗后甲状腺功能监测的充分性

Velez, Maria A; Kang, Elliot S; Thompson, Chester A; Lind-Lebuffe, Jackson; Shen, Collin; Park, Seung Jun; Han, Andy; Gower, Arjan; Li, Daniel; Rochigneux, Philippe; Grogan, Tristan R; Elashoff, David A; Garon, Edward B; Lisberg, Aaron

Author Correction: CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors

作者更正:CTLA4阻断可消除KEAP1/STK11相关的PD-(L)1抑制剂耐药性

Skoulidis, Ferdinandos; Araujo, Haniel A; Do, Minh Truong; Qian, Yu; Sun, Xin; Cobo, Ana Galan; Le, John T; Montesion, Meagan; Palmer, Rachael; Jahchan, Nadine; Juan, Joseph M; Min, Chengyin; Yu, Yi; Pan, Xuewen; Arbour, Kathryn C; Vokes, Natalie; Schmidt, Stephanie T; Molkentine, David; Owen, Dwight H; Memmott, Regan; Patil, Pradnya D; Marmarelis, Melina E; Awad, Mark M; Murray, Joseph C; Hellyer, Jessica A; Gainor, Justin F; Dimou, Anastasios; Bestvina, Christine M; Shu, Catherine A; Riess, Jonathan W; Blakely, Collin M; Pecot, Chad V; Mezquita, Laura; Tabbó, Fabrizio; Scheffler, Matthias; Digumarthy, Subba; Mooradian, Meghan J; Sacher, Adrian G; Lau, Sally C M; Saltos, Andreas N; Rotow, Julia; Johnson, Rocio Perez; Liu, Corinne; Stewart, Tyler; Goldberg, Sarah B; Killam, Jonathan; Walther, Zenta; Schalper, Kurt; Davies, Kurtis D; Woodcock, Mark G; Anagnostou, Valsamo; Marrone, Kristen A; Forde, Patrick M; Ricciuti, Biagio; Venkatraman, Deepti; Van Allen, Eliezer M; Cummings, Amy L; Goldman, Jonathan W; Shaish, Hiram; Kier, Melanie; Katz, Sharyn; Aggarwal, Charu; Ni, Ying; Azok, Joseph T; Segal, Jeremy; Ritterhouse, Lauren; Neal, Joel W; Lacroix, Ludovic; Elamin, Yasir Y; Negrao, Marcelo V; Le, Xiuning; Lam, Vincent K; Lewis, Whitney E; Kemp, Haley N; Carter, Brett; Roth, Jack A; Swisher, Stephen; Lee, Richard; Zhou, Teng; Poteete, Alissa; Kong, Yifan; Takehara, Tomohiro; Paula, Alvaro Guimaraes; Parra Cuentas, Edwin R; Behrens, Carmen; Wistuba, Ignacio I; Zhang, Jianjun; Blumenschein, George R; Gay, Carl; Byers, Lauren A; Gibbons, Don L; Tsao, Anne; Lee, J Jack; Bivona, Trever G; Camidge, D Ross; Gray, Jhannelle E; Leighl, Natasha B; Levy, Benjamin; Brahmer, Julie R; Garassino, Marina C; Gandara, David R; Garon, Edward B; Rizvi, Naiyer A; Scagliotti, Giorgio Vittorio; Wolf, Jürgen; Planchard, David; Besse, Benjamin; Herbst, Roy S; Wakelee, Heather A; Pennell, Nathan A; Shaw, Alice T; Jänne, Pasi A; Carbone, David P; Hellmann, Matthew D; Rudin, Charles M; Albacker, Lee; Mann, Helen; Zhu, Zhou; Lai, Zhongwu; Stewart, Ross; Peters, Solange; Johnson, Melissa L; Wong, Kwok K; Huang, Alan; Winslow, Monte M; Rosen, Michael J; Winters, Ian P; Papadimitrakopoulou, Vassiliki A; Cascone, Tina; Jewsbury, Philip; Heymach, John V

Characteristics of clinical trials associated with appeal and return on investment to participants: a review and framework

影响临床试验吸引力和参与者投资回报的特征:综述与框架

Fernandez Turizo, Maria J; Velez, Maria A; Glenn, Beth; Cummings, Amy L; Segarra-Vazquez, Barbara; Gorbatov, Sarah; Park, Seung J; Shen, Collin; Lind-Lebuffe, Jackson P; Unger, Joseph M; Garon, Edward B

Rationale and design for a phase IIIb trial of first-line tremelimumab plus durvalumab versus pembrolizumab, in combination with chemotherapy, in patients with non-squamous metastatic non-small-cell lung cancer and mutations or co-mutations in STK11, KEAP1, or KRAS: the TRITON study

TRITON 研究:一项 IIIb 期临床试验的理论依据和设计,该试验旨在比较一线使用 tremelimumab 联合 durvalumab 与 pembrolizumab 联合化疗治疗非鳞状细胞转移性非小细胞肺癌且伴有 STK11、KEAP1 或 KRAS 基因突变或共突变的患者,疗效。

Skoulidis, Ferdinandos; Borghaei, Hossein; Garon, Edward B; Leal, Ticiana A; Kaufman, Jacob; Liu, Stephen V; Nadler, Eric; Patel, Sandip Pravin; Peters, Solange; Ricciuti, Biagio; Gautam, Ashish; Emeribe, Ugochinyere; Luciani-Silverman, Luisa; Heymach, John V

RELAY+: Final Overall Survival With Ramucirumab Plus Gefitinib in Patients With Untreated EGFR-Mutated Metastatic NSCLC

RELAY+:雷莫芦单抗联合吉非替尼治疗未经治疗的EGFR突变转移性非小细胞肺癌患者的最终总生存期

Nishio, Makoto; Seto, Takashi; Reck, Martin; Garon, Edward B; Nishio, Kazuto; Kasahara, Kazuo; Nishino, Kazumi; Satouchi, Miyako; Yoh, Kiyotaka; Hayashi, Hidetoshi; Sakai, Kazuko; Enatsu, Sotaro; Matsui, Tomoko; Varughese, Sunoj Chacko; Carlsen, Michelle; Visseren-Grul, Carla; Nakagawa, Kazuhiko